Bridgewater Associates LP Cuts Position in Relx Plc (NYSE:RELX)

Bridgewater Associates LP lessened its position in Relx Plc (NYSE:RELX - Free Report) by 47.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,050 shares of the technology company's stock after selling 22,628 shares during the period. Bridgewater Associates LP's holdings in Relx were worth $1,138,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Arrowstreet Capital Limited Partnership grew its position in shares of Relx by 50.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,968,739 shares of the technology company's stock valued at $89,420,000 after buying an additional 658,655 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in Relx by 2.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,898,927 shares of the technology company's stock worth $86,249,000 after acquiring an additional 48,336 shares in the last quarter. Natixis Advisors LLC boosted its holdings in Relx by 2.8% in the fourth quarter. Natixis Advisors LLC now owns 1,202,592 shares of the technology company's stock worth $54,622,000 after acquiring an additional 32,739 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Relx in the 4th quarter valued at $44,516,000. Finally, Bank of Montreal Can grew its stake in shares of Relx by 290.3% in the 4th quarter. Bank of Montreal Can now owns 886,758 shares of the technology company's stock worth $40,277,000 after acquiring an additional 659,547 shares in the last quarter. Institutional investors and hedge funds own 15.02% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of Relx in a research report on Wednesday, March 26th. They set a "buy" rating for the company. Redburn Atlantic began coverage on shares of Relx in a report on Wednesday, January 8th. They set a "buy" rating on the stock. StockNews.com cut shares of Relx from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Morgan Stanley reissued an "overweight" rating on shares of Relx in a report on Wednesday, April 16th. Finally, Barclays raised shares of Relx from an "equal weight" rating to an "overweight" rating in a report on Friday, March 14th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy".

Relx Price Performance

Shares of RELX traded up $0.35 during mid-day trading on Thursday, reaching $53.05. 212,141 shares of the stock traded hands, compared to its average volume of 680,234. The firm has a fifty day moving average price of $49.44 and a 200 day moving average price of $48.12. The company has a market cap of $98.18 billion, a price-to-earnings ratio of 28.52, a price-to-earnings-growth ratio of 2.73 and a beta of 0.84. The company has a current ratio of 0.52, a quick ratio of 0.47 and a debt-to-equity ratio of 1.46. Relx Plc has a 1 year low of $40.25 and a 1 year high of $53.15.

Relx Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Friday, May 9th will be given a dividend of $0.5586 per share. This is a positive change from Relx's previous semi-annual dividend of $0.23. This represents a dividend yield of 1.6%. The ex-dividend date is Friday, May 9th. Relx's payout ratio is 59.68%.

About Relx

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.